NephroSant hires new lead to market home-based kidney transplant rejection test
Click Here to Manage Email Alerts
NephroSant, a startup operating out of the University of California, San Francisco that developed a test to detect graft rejection following kidney transplantation, has hired Gina Ford, RPh, MBA, as its new chief commercialization officer.
In this role, Ford will lead the company’s global commercialization strategy with a specific focus on bringing the test to market, according to a press release. The test, known as QSant, is the only urine-based kidney rejection test currently available and allows for use at home with one sample.
“I am excited to be joining the NephroSant team to positively impact the kidney transplant market and improve the lives of patients,” Ford said in the release. “I believe that QSant will provide better understanding of the health of a transplanted kidney for both physicians and patients, improving outcomes and extending the life of transplanted organs.”
Some key roles that demonstrate Ford’s preparedness for the role, according to the release, include founding One Joule LLC (a commercial and corporate strategy consulting firm), and serving as vice president of corporate strategy and commercial planning at Crinetics Pharmaceuticals.
“Gina has the leadership experience and proven track record in building and growing companies to full-scale commercialization, which is exactly what we need as we take our business to the next level,” Minnie Sarwal, MD, PhD, CEO and founder of NephroSant, said in the release. “Our recent funding round, coupled with Gina's hiring, will allow us to evolve as a company and elevate our ability to reach and serve our customers and patients.”
In March of 2021, Healio Nephrology reported on the Series A funding round in which DaVita joined other investors to raise $16 million in for QSant. More information on the test, including a feature that generates rejection risk for individual patients, can be found here.
Click Here to Manage Email Alerts